|
|
|
| Vaccines in the News |
|
| Media coverage about vaccines and vaccine-preventable diseases |
|
| Anthrax |
|
|
|
|
|
Drug Gives Anthrax Protection in Animal Studies |
|
| Newsday |
|
| July 9, 2009 |
|
| "A series of studies show an experimental
drug helped monkeys and rabbits survive anthrax, suggesting the drug could
be useful in case of another anthrax attack. In 2001, five people died after
inhaling anthrax germs they'd gotten through the U.S. mail. Doctors now use
antibiotics to prevent or treat anthrax, and there also is an anthrax
vaccine. The experimental drug works a different way - by blocking deadly
anthrax toxin from entering cells. Researchers say it could be combined with
antibiotics. The company that developed the experimental drug under federal
contract has already delivered 20,000 doses to the government for emergency
use..." |
|
|
FDA Assessing Feasibility of Using Nanotechnology Test to Detect Anthrax
Following a Bioterrorist Attack |
|
| FDA News Release |
|
| March 17, 2009 |
|
| "The U.S. Food and Drug
Administration has completed a "proof-of-concept" study of a test that
quickly and accurately detects the presence of even the smallest amount
of the deadly anthrax toxin. "The FDA findings could form the basis of a
test that allows earlier diagnosis of anthrax infection than currently
possible," said Indira Hewlett, Ph.D., the senior author of the study
and chief of the Laboratory of Molecular Virology, Office of Blood
Research and Review, at the FDA's Center for Biologics Evaluation and
Research (CBER). 'The earlier those infected with anthrax can be
treated, the better.' A proof-of-concept study is an initial
investigation that aims to determine if a new scientific idea or concept
holds promise for further development. A report on the results of this
study appears in the March issue of Clinical and Vaccine Immunology..." |
|
|
|
|
|
|
| Rockville Biotech Buys Rival's Anthrax Vaccine |
|
| Washington Post |
|
| May 5, 2008 |
|
| "The effort to protect the country from another anthrax attack will take an unexpected turn today when Rockville firm Emergent BioSolutions plans to announce that it has bought for $2 million an anthrax vaccine from a California company that federal health officials dropped in 2006..." |
|
|
|
|
|
|
|
| Immunization Action Coalition 1573 Selby Avenue Saint Paul, MN 55104 |
|
| tel 651-647-9009 fax 651-647-9131 |
|
| email admin@immunize.org |
|